BLAINJECTIONINJECTABLE
Approved
May 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
9
Mechanism of Action
Erenumab-aooe is a human monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) receptor and antagonizes CGRP receptor function.
Indications (1)
Clinical Trials (5)
Erenumab-aooe for the Management of Trigeminal Neuropathic Pain.
Started May 2022
5 enrolled
Trigeminal Neuropathy
Erenumab-aooe for Temporomandibular Disorders Management: TMD Cgrp Antibody RElief (TMD CARE)
Started May 2022
5 enrolled
Temporomandibular Disorders
Safety and Efficacy of Erenumab-aooe in Patients With Temporomandibular Disorder
Started Nov 2021
30 enrolled
Temporomandibular Disorder
A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine
Started Jun 2021
240 enrolled
Migraine
Aimovig Pregnancy Exposure Registry
Started Jan 2021
2,842 enrolled
Migraine